Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Intact p53-dependent responses in miR-34-deficient mice.

Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A.

PLoS Genet. 2012;8(7):e1002797. doi: 10.1371/journal.pgen.1002797. Epub 2012 Jul 26.

2.

Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Ma X, Choudhury SN, Hua X, Dai Z, Li Y.

Carcinogenesis. 2013 Jun;34(6):1216-23. doi: 10.1093/carcin/bgt044. Epub 2013 Feb 5.

3.

microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.

Zhang C, Liu J, Tan C, Yue X, Zhao Y, Peng J, Wang X, Laddha SV, Chan CS, Zheng S, Hu W, Feng Z.

Oncotarget. 2016 Feb 23;7(8):8783-96. doi: 10.18632/oncotarget.7088.

4.

miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells.

Liu Y, Xing R, Zhang X, Dong W, Zhang J, Yan Z, Li W, Cui J, Lu Y.

DNA Repair (Amst). 2013 Sep;12(9):741-50. doi: 10.1016/j.dnarep.2013.06.002. Epub 2013 Jul 5.

PMID:
23835407
5.

RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.

Chen X, Chen S, Xiu YL, Sun KX, Zong ZH, Zhao Y.

Mol Cancer. 2015 Feb 4;14:31. doi: 10.1186/s12943-015-0304-6.

6.

Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples.

He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):35-40. doi: 10.1016/j.bbrc.2009.07.101. Epub 2009 Jul 24.

PMID:
19632201
7.

Tumor suppressor functions of miR-133a in colorectal cancer.

Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J.

Mol Cancer Res. 2013 Sep;11(9):1051-60. doi: 10.1158/1541-7786.MCR-13-0061. Epub 2013 May 30.

8.

miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Iqbal N, Mei J, Liu J, Skapek SX.

Cell Cycle. 2014;13(5):792-800. doi: 10.4161/cc.27725. Epub 2014 Jan 8.

9.

MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene.

He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ, Yu J.

Mol Med. 2013 Feb 8;18:1491-8. doi: 10.2119/molmed.2012.00304.

10.

p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB.

Zhang Q, Cao LY, Cheng SJ, Zhang AM, Jin XS, Li Y.

Oncol Rep. 2015 Mar;33(3):1335-41. doi: 10.3892/or.2015.3715. Epub 2015 Jan 14.

PMID:
25591821
11.

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW.

PLoS One. 2013 Apr 9;8(4):e61064. doi: 10.1371/journal.pone.0061064. Print 2013.

12.

Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.

Wang W, Cheng B, Miao L, Mei Y, Wu M.

Cell Death Dis. 2013 Apr 4;4:e574. doi: 10.1038/cddis.2013.97.

13.

The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.

Liang HQ, Wang RJ, Diao CF, Li JW, Su JL, Zhang S.

Oncotarget. 2015 Oct 6;6(30):29413-27. doi: 10.18632/oncotarget.5003.

14.

MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism.

Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR.

PLoS One. 2009 Dec 24;4(12):e8445. doi: 10.1371/journal.pone.0008445.

15.

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.

Nittner D, Lambertz I, Clermont F, Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, Schramm A, Schulte JH, Marine JC.

Nat Cell Biol. 2012 Sep;14(9):958-65. doi: 10.1038/ncb2556. Epub 2012 Aug 5.

PMID:
22864477
16.

Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.

Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U, Sozzi G.

Cell Death Dis. 2014 Dec 11;5:e1564. doi: 10.1038/cddis.2014.507.

17.

P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy.

Zhang DG, Zheng JN, Pei DS.

Mol Cancer. 2014 May 21;13:115. doi: 10.1186/1476-4598-13-115. Review.

18.

Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M.

Mol Cell. 2007 Jun 8;26(5):731-43. Epub 2007 May 31.

19.

Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency.

Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li XB, Zhang C, Yang X, Yang ZZ, Yang X.

Nat Commun. 2013;4:2544. doi: 10.1038/ncomms3544.

20.

The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.

Jones SN, Sands AT, Hancock AR, Vogel H, Donehower LA, Linke SP, Wahl GM, Bradley A.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14106-11.

Supplemental Content

Support Center